Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07267819 · ClinicalTrials.gov registry record
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
A clinical trial of Traumatic Brain Injury and Migraine, sponsored by Uniformed Services University of the Health Sciences.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07267819 is a study of Traumatic Brain Injury and Migraine that is actively recruiting participants, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 60 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07267819, a study of Traumatic Brain Injury and Migraine, is actively recruiting participants, sponsored by Uniformed Services University of the Health Sciences.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This cohort study aims to compare the efficacy of Xeomin injections for migraine management in patients with a history of Traumatic Brain Injury (TBI) versus those with a history of Anomalous Health Incidents (AHI). The study will be conducted at the National Intrepid Center of Excellence (NICOE) in Bethesda, MD. The primary objective is to determine if Xeomin injections result in different outcomes for migraine management between TBI and AHI patients. This is a combined retrospective and prospective cohort study design. Patients scheduled for Xeomin treatments will be categorized into TBI and AHI groups. For the prospective cohort, participants will complete a baseline questionnaire, receive their scheduled Xeomin treatment, and participate in follow-up interviews at 4-6 weeks and 10-12 weeks post-treatment. For the retrospective cohort, similar information will be acquired from existing records. Statistical analysis will compare migraine characteristics and treatment responses between the two groups. All data will be de-identified to protect patient privacy.
Conditions Studied
Interventions
- DRUG Xeomin (incobotulinumtoxinA)
Study Locations (1)
Maryland
- National Intrepid Center of Excellence (NICOE) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2028-06-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07267819
The ClinicalTrials.gov registry entry for NCT07267819 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (78% lower). The listed sponsor is Uniformed Services University of the Health Sciences, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which Xeomin (incobotulinumtoxinA) is the first listed.
NCT07267819 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07267819 about?
NCT07267819 is a clinical study titled "Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents". This cohort study aims to compare the efficacy of Xeomin injections for migraine management in patients with a history of Traumatic Brain Injury (TBI) versus those with a history of Anomalous Health Incidents (AHI). The study will be conducted at the National Intrepid Center of Excellence (NICOE) in...
What is the current status of trial NCT07267819?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-08-05. Estimated completion is 2028-06-06.
What conditions does trial NCT07267819 study?
This clinical trial studies the following conditions: Traumatic Brain Injury, Migraine, Anomalous Health Incidents.
What interventions are being tested in trial NCT07267819?
The interventions under investigation include: Xeomin (incobotulinumtoxinA) (DRUG).
Who is sponsoring clinical trial NCT07267819?
This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07267819 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
tPBM in Older Adults With Traumatic Brain Injury
RECRUITING · NA
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Carbon Dioxide Administration and Brain Waste Clearance
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Cortical Spreading Depolarization After Severe Traumatic Brain Injury
RECRUITING
-
A Study to Evaluate the SENSE Device's Ability to Detect TBI
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.